From: Consensus clustering applied to multi-omics disease subtyping
Cancer | Scenarios | Enriched clinical labels |
---|---|---|
AML | Both | Age at initial pathologic diagnosis |
CALGB cytogenetics risk category | ||
Leukemia French–American–”British Morphology Code | ||
BIC | Both | Age at initial pathologic diagnosis, PAM50 call |
Pathologic N, Pathologic Stage, Histological type | ||
Estrogen receptor status, Progesterone receptor status | ||
StoM All | Pathologic M, Pathologic T | |
COAD | MtoM | Histological type |
StoM All | Age at initial pathologic diagnosis | |
GBM | Both | None |
KIRC | Both | Pathologic M, Neoplasm histologic grade |
StoM All | Pathologic T | |
LIHC | Both | Gender, Age at initial pathologic diagnosis, Fetoprotein outcome value |
LUSC | Both | None |
OV | Both | None |
SARC | Both | Gender, Age at initial pathologic diagnosis, Histological type |
MtoM | New neoplasm event type | |
SKCM | MtoM | Age at initial pathologic diagnosis |